Raymond James Financial
LRMR icon

Raymond James Financial’s Larimar Therapeutics LRMR Stock Holding History

Raymond James Financial’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.3K Buy
+10,577
New +$42K ﹤0.01% 5301
2025
Q3 		– Sell
-8,000
Closed -$23.1K – 5961
2025
Q2 		$23.1K Buy
+8,000
New +$18.5K ﹤0.01% 5541

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Raymond James Financial's LRMR Position: Q2 2026 in Review

Raymond James Financial opened a new position in Larimar Therapeutics (LRMR) in Q2 2026: 10,577 shares worth $32.3K. The stake represents ﹤0.01% of the portfolio and ranks #5301 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in LRMR as recently as Q2 2025.

Raymond James Financial first reported a position in LRMR in Q2 2025 and has held it in 2 quarters since. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Raymond James Financial held 10,577 shares of Larimar Therapeutics worth $32.3K as of Q2 2026.
  • Larimar Therapeutics was a new Raymond James Financial position in Q2 2026.
  • Larimar Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5301 holding.
  • Raymond James Financial first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.